BioAtla, Inc. (BCAB) stock
BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
BioAtla operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BioAtla's operating cash flow for the twelve months ending Jun 30, 2026 was -$23.48M. For fiscal 2025 it was -$48.20M. The highest annual figure on record is -$9.65M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.20M | – |
| FY2024 | Dec 31, 2024 | -$71.94M | – |
| FY2023 | Dec 31, 2023 | -$104.02M | – |
| FY2022 | Dec 31, 2022 | -$90.42M | – |
| FY2021 | Dec 31, 2021 | -$62.21M | – |
| FY2020 | Dec 31, 2020 | -$36.33M | – |
| FY2019 | Dec 31, 2019 | -$9.65M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$419.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.78M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.65M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.35M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.14M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.95M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.73M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.99M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.01M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.05M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.81M | – |
See a number that looks wrong?